NK cell subsets and CD107a mobilization assay
We read with interest, in a recent issue of Leukemia, the paper by Penack et al 1 about the validation of CD107a as a functional marker for natural killer (NK) cell activity. As in cytotoxic T cells, CD107a was shown by flow cytometry to be expressed at the cell surface as a consequence of degranulation of lytic granules, it was of course very interesting to check if this molecule would also appear on NK cells, another cytotoxic lymphocyte subset, upon target cell encounter. Indeed, the authors describe that after a few hours of incubation with the prototype NK cell target, the HLA class I-deficient myeloid leukemia cell line K562, up to 6% of fresh peripheral blood CD56 þ cells are CD107a þ , in contrast to 0% in the absence of target cells, as assessed by flow cytometry.
Until there, the results are compatible with those described by Alter et al, 2 who performed essentially the same assay with the same protocol and the same target, K562. However, their percentage of CD107a þ NK cells is considerably higher, and the optimal effector to target ratio is 10/1 and not 1/1 as in the paper by Penack et al. 1 Interestingly, the latter do not cite this work although it was published online a month before they submitted their paper.
A point of major concern is that Penack et al 1 stained the lymphocytes analyzed, according to the Methods section of their paper, only with monoclonal antibodies (mAbs) to CD16 and CD56 (and of course to CD107a), but not, as do Alter et al, 2 with an anti-CD3 mAb. The problem when omitting an anti-CD3 staining is that human peripheral blood contains a population of CD3 þ CD56 þ T lymphocytes 3,4 that represents 2.5-3% of peripheral blood mononuclear cells (PBMC) 3, 4 and a mean between donors of 24% of all CD56 þ cells. 3 This subset of CD56 þ cells is thus far from anecdotic and should not be ignored. When Penack et al 1 claim that they gate on CD56 þ NK cells, up to 25% of the gated cells might in fact be T cells. As it has been described that CD3 þ CD56 þ T cells display a non-MHC-restricted cytotoxicity just as NK cells do and that in particular they spontaneously kill K562 targets, 3, 4 although others claim that a stimulation with IL-2 or IL-15 is first necessary, 5 they are expected to become CD107a þ upon incubation with this target. Thus, it cannot be concluded from the results of Penack et al 1 if the CD107a þ cells are NK cells or T cells.
Based on CD16 and CD56 expression, the authors 1 then isolate three different 'NK' cell subsets and check CD107a expression in the three subpopulations. Here again, CD3 þ cells are not gated out, so that the percentage of CD3 þ CD56 þ T cells within the CD56 dim CD16À subset might be even further increased compared to the total CD56 þ cells. In an ongoing research project about NK cell subsets (manuscript in preparation), we regularly study CD16 vs CD56 expression, but in order to avoid contamination by CD3 þ CD56 þ T cells, we gate out CD3 þ T and even CD19 þ B lymphocytes, as shown in Figure 1 . In this graph that displays results obtained with samples from two representative normal donors, the left panels are those where the gate is set on the entire lymphocyte population. The population of CD56 dim CD16À cells is quite well represented in region 1 (R1), as is the case in the comparable figure shown by Penack et al. 1 However, after gating out T and B cells (right panels), it becomes obvious that most of the cells in R1 must be CD3 þ T cells, because they can no longer be found when the gate is truly set on NK cells. In fact, there are only very few CD56 dim CD16À cells remaining. Therefore, it is once more impossible to know if the CD107a þ cells among the CD56 In order to demonstrate that the CD107a þ cells correspond to the cytotoxic population, Penack et al 1 separate CD107a þ and CD107aÀ cells and compare the cytotoxic activity of both subsets. However, before sorting these two cell types, they first isolate CD56 þ cells from PBMC by an immunomagnetic technique with anti-CD56 beads. This means that the CD3 þ CD56 þ T cells are again not separated from the NK cells in this type of assay. Cytotoxicity correlates with CD107a expression, as also shown by Alter et al, 2 but one more time it is not clear if the cytotoxic activity is performed by NK cells or by contaminating T cells.
In the paper by Alter et al, 2 not only are the total percentages of CD107a þ NK cells higher (it should again be stressed that in this work, CD56 þ CD3À T cells have been gated out) but also a significant percentage of CD56 bright NK cells becomes CD107a þ upon target cell-mediated activation.
A further surprise is that based on these results, 1 one would have to conclude that CD56 dim CD16 þ NK cells, which represent the majority of the CD107aÀ cells based on the data shown by Penack et al, 1 are not cytotoxic at all towards K562 targets. In other words, if the authors 1 are right, all natural cytotoxic activity of NK cells would be confined to a very minor subset with the CD56 dim CD16À phenotype, although its cytotoxic activity has indeed been described. 4 So far, so good, except that Nagler et al 6 have convincingly shown that freshly isolated purified CD56 dim CD16 þ NK cells display a very strong cytotoxicity towards K562, and that even CD56 bright NK cells kill the same target to some extent. Different subsets of CD56 þ and CD16 þ cells among peripheral blood lymphocytes. PBMC from two normal donors (0802 and A2B12) were isolated from venous blood by density gradient centrifugation, washed and prepared for three-color flow cytometry analysis by staining with fluorochrome-conjugated mAbs. The mAb-fluorochrome conjugates used were CD16/FITC, CD56/PE, CD3/PE-Cy5 and CD19/PECy5. Samples were analyzed on a FACSCaliburt flow cytometer with CellQuestt software. For analysis, a first gate was set on lymphocytes based on forward and side scatter characteristics. Then, total lymphocytes were checked for expression of CD56 and CD16 (left panels). The majority of cells are located in the lower left quadrants of the dot plots and correspond to T cells (CD3 þ CD56ÀCD16À) and B cells (CD19 þ CD56ÀCD16À). A significant proportion of cells (but with variations between donors) with the phenotype CD56 dim CD16À can be found in region 1 (R1). These dot plots closely resemble the one shown by Penack et al 1 in Figure 3a , in particular with respect to the abundant CD56 dim CD16À population. In a second step, all T (CD3 þ ) and B (CD19 þ ) lymphocytes were gated out, and the remaining cells were again analyzed for CD56 vs CD16 expression (right panels). Region 2 (R2), the equivalent of R1 when total lymphocytes are considered, is obtained after gating out T and B cells and contains very few events. Thus, most of the cells present in R1 are likely to be CD3 þ CD56 þ T lymphocytes, a population previously described in the literature. 3 In summary, before all immunologists will be convinced of the need of a paradigm shift, establishing that all of a sudden the major CD56 dim CD16 þ NK cell population is no longer cytotoxic towards tumour targets, better-performed studies with adequate control experiments seem to be necessary. 
